Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

therapeuticsmd - TXMD

TXMD

Close Chg Chg %
1.64 0.02 1.22%

Open Market

1.66

+0.02 (1.22%)

Volume: 26.80K

Last Updated:

Dec 31, 2025, 1:05 PM EDT

Trade Now

Company Overview: therapeuticsmd - TXMD

TXMD Key Data

Open

$1.67

 Day Range

1.63 - 1.68

52 Week Range

0.70 - 2.44

 Market Cap

$18.98M

Shares Outstanding

11.57M

 Public Float

11.40M

Beta

0.41

 Rev. Per Employee

N/A

P/E Ratio

64.37

 EPS

$0.03

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

58.47K

  

TXMD Performance

1 Week
 
 -5.75%
 
1 Month
 
 -3.53%
 
3 Months
 
 52.94%
 
1 Year
 
 90.70%
 
5 Years
 
 -97.29%
 

TXMD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About therapeuticsmd - TXMD

TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.

TXMD At a Glance

TherapeuticsMD, Inc.
951 Yamato Road
Boca Raton, Florida 33431
Phone 1-561-961-1900 Revenue 1.76M
Industry Pharmaceuticals: Major Net Income -2,181,000.00
Sector Health Technology 2024 Sales Growth 35.253%
Fiscal Year-end 12 / 2025 Employees 1
View SEC Filings

TXMD Valuation

P/E Current 64.368
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 5.632
Price to Book Ratio 0.362
Price to Cash Flow Ratio 13.55
Enterprise Value to EBITDA -4.034
Enterprise Value to Sales 6.833
Total Debt to Enterprise Value 0.596

TXMD Efficiency

Revenue/Employee 1,761,000.00
Income Per Employee -2,181,000.00
Receivables Turnover 0.494
Total Asset Turnover 0.043

TXMD Liquidity

Current Ratio 1.921
Quick Ratio 1.921
Cash Ratio 0.979

TXMD Profitability

Gross Margin 71.096
Operating Margin -198.296
Pretax Margin -133.049
Net Margin -123.85
Return on Assets -5.63
Return on Equity -8.161
Return on Total Capital -6.693
Return on Invested Capital -6.728

TXMD Capital Structure

Total Debt to Total Equity 26.215
Total Debt to Total Capital 20.77
Total Debt to Total Assets 18.482
Long-Term Debt to Equity 20.248
Long-Term Debt to Total Capital 16.043
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Therapeuticsmd - TXMD

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
86.95M 69.96M 1.30M 1.76M
Sales Growth
+34.03% -19.54% -98.14% +35.25%
Cost of Goods Sold (COGS) incl D&A
18.84M 1.40M 922.00K 509.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.09M 1.19M 922.00K 509.00K
Depreciation
- 800.00K 600.00K 100.00K
Amortization of Intangibles
3.29M 593.00K 822.00K 509.00K
COGS Growth
+10.70% -92.58% -34.00% -44.79%
Gross Income
68.11M 68.57M 380.00K 1.25M
Gross Income Growth
+42.33% +0.67% -99.45% +229.47%
Gross Profit Margin
+78.33% +98.00% +29.19% +71.10%
2021 2022 2023 2024 5-year trend
SG&A Expense
207.88M 57.90M 8.90M 4.74M
Research & Development
- - - 7.09M
-
Other SG&A
200.80M 57.90M 8.90M 4.74M
SGA Growth
+2.21% -72.15% -84.62% -46.71%
Other Operating Expense
- - - -
-
Unusual Expense
- - 9.47M 1.27M
-
EBIT after Unusual Expense
(139.77M) 1.19M (8.52M) (4.76M)
Non Operating Income/Expense
272.00K (117.00K) 981.00K 2.43M
Non-Operating Interest Income
- - 300.00K 144.90K
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 32.92M 200.00K 9.50K
Interest Expense Growth
- +15.17% -100.00% -95.25%
Gross Interest Expense
- 32.92M 200.00K 9.50K
Interest Capitalized
- - - -
-
Pretax Income
(172.41M) 1.07M (7.74M) (2.34M)
Pretax Income Growth
+6.05% +100.62% -820.86% +69.74%
Pretax Margin
-198.29% +1.54% -594.62% -133.05%
Income Tax
- - (43.00K) (31.00K)
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(172.41M) 1.07M (7.70M) (2.31M)
Minority Interest Expense
- - - -
-
Net Income
(172.41M) 1.07M (7.70M) (2.31M)
Net Income Growth
+6.05% +100.62% -816.85% +69.97%
Net Margin Growth
-198.29% +1.54% -591.32% -131.29%
Extraordinaries & Discontinued Operations
- (94.49M) (2.58M) 131.00K
Discontinued Operations
- (94.49M) (2.58M) 131.00K
Net Income After Extraordinaries
(172.41M) (93.42M) (10.28M) (2.18M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(172.41M) (93.42M) (10.28M) (2.18M)
EPS (Basic)
-21.6605 -10.3476 -0.9844 -0.1891
EPS (Basic) Growth
+34.93% +52.23% +90.49% +80.79%
Basic Shares Outstanding
7.96M 9.03M 10.44M 11.53M
EPS (Diluted)
-21.6605 -10.3476 -0.9844 -0.1891
EPS (Diluted) Growth
+34.93% +52.23% +90.49% +80.79%
Diluted Shares Outstanding
7.96M 9.03M 10.44M 11.53M
EBITDA
(135.68M) 11.86M (7.60M) (2.98M)
EBITDA Growth
+9.59% +108.74% -164.11% +60.76%
EBITDA Margin
-156.04% +16.95% -583.79% -169.39%

Insider Actions for Therapeuticsmd - TXMD

Date Name Shares Transaction Value
Apr 15, 2025 Tommy George Thompson Director 14,779 Open market or private purchase of non-derivative security Non-derivative transaction at $1 per share 14,779.00
Apr 15, 2025 Marlan D. Walker Chief Executive Officer 73,639 Open market or private purchase of non-derivative security Non-derivative transaction at $1 per share 73,639.00
Feb 21, 2025 Tommy George Thompson Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 21, 2025 Cooper C. Collins Director 60,516 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 21, 2025 Cooper C. Collins Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 21, 2025 Gail K. Naughton Director 8,500 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 21, 2025 Gail K. Naughton Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 21, 2025 Marlan D. Walker Chief Executive Officer 68,343 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 21, 2025 Marlan D. Walker Chief Executive Officer 69,113 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 21, 2025 Marlan D. Walker Chief Executive Officer 70,846 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 21, 2025 Marlan D. Walker Chief Executive Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 21, 2025 Marlan D. Walker Chief Executive Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 21, 2025 Marlan D. Walker Chief Executive Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 21, 2025 Marlan D. Walker Chief Executive Officer 1,733 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Therapeuticsmd in the News